Infinity Pharmaceuticals has reported positive results from preclinical and Phase I studies of IPI-549 at the Keystone Symposia Conference.

IPI-549 is an investigational oral immuno-oncology drug designed to treat advanced solid tumours by selectively inhibiting phosphoinositide-3-kinase-gamma (PI3K-gamma).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The data from preclinical study indicated that IPI-549 effects the myeloid cells and remodels the immune-suppressive tumour microenvironment, resulting in elimination of the resistance to immune checkpoint blockade.

The results from the Phase I study conducted in nine patients showed positive safety, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy.

"The results from the Phase I study conducted in nine patients showed positive safety, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy."

The Phase I study involves the evaluation of IPI-549 as a monotherapy and in combination with a PD-1 immune checkpoint inhibitor Opdivo, in patients with advanced solid tumours.

Infinity Pharmaceuticals biology and translational science vice-president Jeffery Kutok said: "The data presented suggest that targeting PI3K-gamma by IPI-549 within immune-suppressive myeloid cells in the tumour microenvironment could offer a unique way to both enhance the activity of checkpoint inhibition in sensitive tumours, as well as to overcome tumour resistance to checkpoint inhibition.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Infinity is excited to be at the forefront of developing a potentially transformative approach within immuno-oncology, and we look forward to reporting additional data from our Phase I study of IPI-549 later this year."

The firm intends to further base its Phase I study in patients with non-small-cell lung cancer (NSCLC), melanoma, and squamous cell carcinoma of the head and neck (SCCHN), on the data from the preclinical study.